Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236844 | 0.87 | PKM (0.55) | PKMTAS1R3TAS1R1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4238811 | 0.85 | PKM (0.50) | PKMCYP2C9CYP2C19TAS1R3TAS1R1 | |
| SCHEMBL4237265 | 0.81 | TAS1R3 (0.52) | PKMMAPK1TAS1R3TAS1R1KDM4E | |
| SCHEMBL4236386 | 0.81 | PKM (0.53) | PKMCYP2C9CYP2C19TAS1R3TAS1R1 | |
| SCHEMBL4227928 | 0.80 | PKM (0.69) | PKMCYP2C9CYP2C19MAPK1TAS1R3 | |
| SCHEMBL4784915 | 0.79 | EPHX1 (0.54) | ALDH1A1MTNR1BEPHX2 | |
| SCHEMBL4226948 | 0.78 | PKM (0.53) | PKMTAS1R3TAS1R1ALDH1A1MTNR1B | |
| SCHEMBL4236704 | 0.78 | PKM (0.66) | PKMCYP2C9CYP2C19MAPK1TAS1R3 | |
| SCHEMBL5151849 | 0.77 | PKM (0.51) | PKMCYP2C9CYP2C19MAPK1TAS1R3 | |
| SCHEMBL4242236 | 0.76 | PKM (0.56) | PKMMAPK1TAS1R3TAS1R1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | PKM 1734/4885CYP2C9 1439/4885CYP2C19 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.